Nuformix Plc (GB:NFX)
LSE:NFX
Want to see GB:NFX full AI Analyst Report?
NFX Stock Chart & Stats
0.23 p
<0.01 p(2.11%)
At close: 4:00 PM EST
0.23 p
<0.01 p(2.11%)
Day’s Range― - ―
52-Week Range0.07 p - 0.56 p
Previous CloseN/A
Volume1.00M
Average Volume (3M)97.88M
Market Cap
£4.70M
Enterprise Value3.70M
Total Cash (Recent Filing)£97.55K
Total Debt (Recent Filing)£0.00
Price to Earnings (P/E)―
Beta-0.11
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding2,609,750,000
10 Day Avg. Volume69,476,590
30 Day Avg. Volume97,880,797
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)5.17
Price to Sales (P/S)0.00
P/FCF Ratio-6.35
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Zero DebtZero reported debt materially lowers financial risk and preserves strategic optionality. For a pre-revenue biotech, this debt-free position buys time to pursue partnerships or non-dilutive funding, reducing near-term insolvency risk and improving negotiating leverage over 2–6 months.
Focused Repurposing Business ModelTargeting repurposing and reformulation is a structural advantage: it can shorten development timelines, lower R&D failure risk versus novel molecules, and increase partnerability. This business model supports repeated out-licensing opportunities and pragmatic capital deployment.
Improving Loss Trend In Latest YearA materially smaller net loss in 2025 versus 2024 indicates management has tightened costs or eliminated one-offs, showing operational discipline. If sustained, this improves runway prospects and reduces near-term external funding pressure over the medium term.
Bears Say
No Recent RevenueThe absence of revenue across multiple years shows a stalled commercialization profile and means the company remains reliant on development milestones or external capital. Lack of product sales impairs self-sustainability and heightens execution risk over months ahead.
Persistent Negative Cash FlowConsistent negative operating and free cash flow signals ongoing cash burn and a structural funding need. This pattern makes the company dependent on equity raises, partnerships, or grants and increases dilution or financing risk within a 2–6 month horizon.
Shrinking Equity And Small Asset BaseA materially reduced equity base and minimal assets leave a thin financial buffer against setbacks. Even with zero debt, the small balance sheet limits investment capacity, magnifies downside from development delays, and tightens tolerances for funding gaps.
Nuformix Plc News
NFX FAQ
What was Nuformix Plc’s price range in the past 12 months?
Nuformix Plc lowest share price was 0.07 p and its highest was 0.56 p in the past 12 months.
What is Nuformix Plc’s market cap?
Nuformix Plc’s market cap is £4.70M.
When is Nuformix Plc’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Nuformix Plc’s earnings last quarter?
Currently, no data Available
Is Nuformix Plc overvalued?
According to Wall Street analysts Nuformix Plc’s price is currently Overvalued.
Does Nuformix Plc pay dividends?
Nuformix Plc does not currently pay dividends.
What is Nuformix Plc’s EPS estimate?
Nuformix Plc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Nuformix Plc have?
Nuformix Plc has 2,609,750,000 shares outstanding.
What happened to Nuformix Plc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Nuformix Plc?
Currently, no hedge funds are holding shares in GB:NFX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Nuformix Plc
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications. Nuformix plc was founded in 2008 and is based in London, the United Kingdom.
Technical Analysis
Evgen Pharma
―
Futura Medical
―
ImmuPharma
―
OptiBiotix Health
―
HemoGenyx Pharmaceuticals Plc
―